New preliminary data from Moleculin Biotech’s pivotal Phase II/III MIRACLE trial has unveiled encouraging results for Annamycin in combination with cytarabine (AnnAraC) for adult patients battling relapsed or refractory acute myeloid leukemia (r/r AML). The study, which is being conducted across multiple sites in the EU and US, suggests a significant improvement in remission rates, particularly in a challenging patient subset with prior treatment failures.
The ongoing MIRACLE trial is designed to rigorously assess the efficacy and safety of AnnAraC in a patient population that has limited and often unsatisfactory treatment options. The initial blinded data from Part A of the trial, which involves a comparison of two Annamycin dosing regimens against cytarabine plus placebo, has provided a beacon of hope for patients with r/r AML.
Key Findings from Part A of the MIRACLE Trial
In an analysis of 62 evaluable patients, the investigational AnnAraC treatment demonstrated a complete remission (CR) rate of 24%. Furthermore, the composite complete remission (CRc) rate, which includes CR with incomplete hematologic recovery, reached an impressive 37%. These figures represent a notable uplift compared to the established benchmarks for salvage therapy in this difficult-to-treat patient group.
A particularly significant aspect of the preliminary findings lies within a subset of 30 patients who had previously experienced treatment failure with first-line venetoclax-based regimens. This subgroup is known to have a very poor prognosis, with published salvage remission rates hovering around a mere 13%. The fact that AnnAraC has shown promising activity in these heavily pre-treated patients offers a potential new lifeline. Median survival in this venetoclax-refractory population is often estimated at a grim 2.4 months, underscoring the critical need for effective salvage options.
Chronology of the MIRACLE Trial and Annamycin Development
The development of Annamycin, a novel anthracycline antibiotic, has been driven by the urgent need for improved therapies in AML, especially for patients who have exhausted conventional treatment avenues. The MIRACLE trial represents a crucial step in this development pathway.
Moleculin Biotech initiated dosing for its Phase III MIRACLE trial of Annamycin with cytarabine for treating AML in April 2025. This marked the commencement of the pivotal stage, aiming to confirm the efficacy and safety of the combination therapy in a larger patient cohort.
Part A of the MIRACLE trial, from which the current preliminary data has been drawn, is designed to evaluate two distinct dosing regimens of Annamycin in combination with cytarabine. These are being compared against a control arm receiving cytarabine plus placebo. A key feature of Part A’s protocol is that all patients receive only one cycle of therapy. This design allows for an initial assessment of efficacy and tolerability without the complexities of multiple treatment cycles, providing a focused look at the drug’s immediate impact.
The enrollment for Part A is progressing steadily, with 74 out of a planned 90 subjects having been enrolled to date. The company anticipates the conclusion of Part A treatment by September 2026. Following this, comprehensive unblinded results are targeted for release between December 2026 and February 2027, which will provide a more definitive picture of the treatment’s performance.
The MIRACLE study itself is a multi-center trial, actively recruiting patients at clinical sites located in the European Union, the United States, and additional European countries. This broad geographical reach ensures that the study’s findings will be generalizable to a diverse patient population. The trial’s eligibility criteria are specifically designed to include AML patients who have received a single prior induction therapy, a group that often faces limited subsequent treatment choices.
Supporting Data and Comparative Efficacy
The reported remission rates from Part A of the MIRACLE trial are particularly noteworthy when contrasted with existing treatment outcomes for relapsed or refractory AML.
- Complete Remission (CR) Rate: 24%
- Composite Complete Remission (CRc) Rate: 37%
These figures gain further significance when examined in the context of the venetoclax-refractory subgroup. For these patients, who have already failed a venetoclax-based regimen, published salvage remission rates are typically around 13%. The observed rates with AnnAraC in this challenging group, while still preliminary and from a blinded analysis, suggest a potential doubling or more of the remission likelihood.
The protocol for Part A involves a single cycle of therapy for all patients. This single-cycle approach allows for an initial evaluation of the drug’s impact without the potential confounding factors of repeated treatments, making the observed remission rates a strong indicator of the drug’s inherent activity.
Official Responses and Expert Commentary
The preliminary results have been met with cautious optimism by Moleculin Biotech’s leadership. Walter Klemp, Chairman and CEO of Moleculin, emphasized the significance of the blinded data in the context of the ongoing trial.
"Because this analysis is still blinded and includes control-arm subjects, we would expect it to sit below the unblinded Annamycin-arm results we reported in June," Klemp stated. "That it has held in a narrow band while the population became measurably harder to treat is what gives us added confidence as we approach the completion of Part A."
This statement highlights the rigorous nature of clinical trial reporting and the expectation that unblinded data from the active treatment arm will likely show even more pronounced benefits. The fact that the current blinded data, which includes the control arm, remains robust in the face of an increasingly challenging patient profile is a positive signal.
Furthermore, Klemp addressed a critical differentiating factor of Annamycin: its safety profile, particularly concerning cardiotoxicity. "Just as importantly, based on reported ejection fractions and adverse events, we continue to observe no evidence of cardiotoxicity, one of the defining characteristics that differentiates Annamycin from conventional anthracyclines," he added.
Cardiotoxicity is a well-documented and dose-limiting side effect of traditional anthracycline chemotherapy, such as daunorubicin and doxorubicin. This adverse event can lead to serious heart problems, significantly impacting patient quality of life and survival. The absence of observed cardiotoxicity with Annamycin, as reported in this trial, is a crucial clinical advantage and a testament to its novel molecular structure and mechanism of action.
Implications and Future Outlook
The preliminary findings from the MIRACLE trial hold significant implications for the treatment landscape of relapsed and refractory AML. If these positive trends are confirmed in the unblinded data and subsequent analyses, AnnAraC could emerge as a much-needed therapeutic option for patients who have exhausted standard treatment pathways, particularly those who have failed venetoclax.
The potential to achieve higher remission rates with a favorable safety profile, especially the absence of cardiotoxicity, would represent a major advancement. This could translate into improved patient outcomes, longer survival, and enhanced quality of life for individuals battling this aggressive form of leukemia.
The completion of Part A of the MIRACLE trial and the subsequent release of unblinded data are eagerly anticipated by the medical community and patients alike. These results will be instrumental in guiding further clinical development and potentially paving the way for regulatory approval. The ongoing enrollment and progress of the trial underscore Moleculin Biotech’s commitment to addressing the unmet needs in AML treatment.
The success of Annamycin in this challenging patient population could redefine salvage therapy for r/r AML and offer a renewed sense of hope for patients facing a disease with historically limited treatment options. The coming months, leading up to the unblinded results in late 2026 and early 2027, will be critical in determining the future impact of AnnAraC on the fight against acute myeloid leukemia.
About the Author
